Core Scientific, Inc.

Core Scientific, Inc.

12.01
EUR
-0.34
(-2.74%)
-3.50EPS
Nov 05Next Earn

Important Dates

Core Scientific Inc's next confirmed earnings release is scheduled for November 5, 2026.

Earnings Date11/5/2026

Share Statistics

As of June 30, 2026, Core Scientific Inc has 319.59M shares outstanding.

Shares Outstanding319.59M

Financial Position

As of June 30, 2026, Core Scientific Inc maintains a current ratio of 0.89, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -177.65, indicating conservative leverage, while an interest coverage ratio of -103.95 demonstrates limited ability to service its debt obligations.

Current Ratio0.89
Quick Ratio0.79
Debt / Equity-177.65
Debt / EBITDA-8.51
Interest Coverage-103.95

Financial Efficiency

EUR

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -39.59, reflecting losses generated across the asset base. The company generates approximately 1.19M in revenue per employee across its workforce of 325.00, a quick read on workforce productivity versus industry peers.

Return on Assets (ROA)-39.59
Revenue Per Employee1.19M
Employee Count325.00

Taxes

EUR

Over the twelve months ended June 30, 2026, Core Scientific Inc recorded 2.39M in income tax expense. The company reported a pretax loss of -1.25B and -1.25B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax2.39M

Income Statement

EUR

Over the twelve months ended June 30, 2026, Core Scientific Inc generated 385.40M in revenue and converted that into -1.25B in net income, yielding earnings per share of -3.50. EBITDA reached -441.92M, while operating income came in at -180.22M.

Revenue385.40M
Gross Profit109.25M
Operating Income-180.22M
Pretax Income-1.25B
Net Income-1.25B
EBITDA-441.92M
EBIT-507.43M
Earnings Per Share (EPS)-3.50

Balance Sheet

EUR

As of June 30, 2026, Core Scientific Inc holds 1.55B in cash and equivalents against 3.76B in total debt, resulting in a net debt position of 2.21B. Total book value stands at -2.12B, with working capital of -257.47M providing operational flexibility.

Cash & Cash Equivalents1.55B
Total Debt3.76B
Net Debt2.21B
Equity (Book Value)-2.12B
Book Value Per Share-6.63
Working Capital-257.47M

Cash Flow

EUR

Core Scientific Inc produced 451.48M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.30B in capital expenditures, free cash flow totaled -847.27M - equivalent to -2.63 per share.

Operating Cash Flow451.48M
Capital Expenditures-1.30B
Free Cash Flow-847.27M
FCF Per Share-2.63

Margins

Over the twelve months ended June 30, 2026, Core Scientific Inc posted a gross margin of 28.35, reflecting its pricing power and cost economics. The operating margin of -46.76 and net profit margin of -325.31 provide insight into operational efficiency.

Gross Margin28.35
Operating Margin-46.76
Pretax Margin-324.69
Profit Margin-325.31
EBITDA Margin-114.67